诺泰生物(688076) - 2025 Q1 - 季度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders of the parent company for Q1 2025 to be between 130 million and 170 million CNY, representing an increase of 63.67 million to 103.67 million CNY, or a year-on-year growth of 96% to 156%[4] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses for Q1 2025 is also projected to be between 130 million and 170 million CNY, reflecting an increase of 64.60 million to 104.60 million CNY, or a year-on-year growth of 99% to 160%[4] - In Q1 2024, the company reported a total profit of 80.45 million CNY and a net profit attributable to shareholders of the parent company of 66.33 million CNY[6] Revenue Growth - The company attributes the significant growth in sales revenue of peptide raw materials to its operational philosophy of "time-leading, technology-leading" and the competitive advantage of its interdisciplinary and international business development team[8] - The company has expanded its high-quality customer base during the reporting period, contributing to the revenue growth[8] Financial Reporting and Uncertainties - The profit forecast is based on preliminary calculations by the company's finance department and has not been audited by registered accountants[9] - There are uncertainties regarding the recognition of revenue for some orders due to factors such as shipping and logistics[9] - The preliminary financial data provided is subject to change and the final figures will be disclosed in the official Q1 2025 report[10]